Entelo Bio
entelo.bioDecoding musculoskeletal disease with deep science and machine learning
Entelo Bio leverage proprietary technology and machine learning to decode the biology of musculoskeletal disease and uncover new transformative therapies in this critical area of unmet need.
The Entelo Bio Team combines scientific excellence with commercial expertise to advance long-read sequencing and MSK research.
Key facts
In portfolio since
2024
Location
Oxford, England
Sector
AI-Driven Healthcare
Why it matters
Over 1.7 billion people live with MSK conditions today, many of which are chronic and debilitating. Effective treatment options remain scarce. Patients are often left with chronic pain and disability, while clinicians are calling for new treatments. The impact is particularly acute for female patients: in 2019, prevalence of MSK disorders was 50% higher in females than males.